AI-driven de novo design system for small protein drugs

Innovent says it has developed an AI-driven de novo design closed-loop system dedicated to small protein drug development. The same report says the system enables intelligent iteration from target elucidation to molecular optimization and has demonstrated a magnitude-level improvement in hit rates and R&D iteration speed in internal projects.